Huonslab Achieves Last-Patient-In (LPI) in Phase 1 Pivotal Study for Recombinant Human Natural Hyaluronidase PH20

Huonslab, a subsidiary of Huons Global (KOSDAQ:084110), has completed patient enrollment in its Phase 1 clinical trial for HLB3-002 (Hydizyme™), a recombinant human natural hyaluronidase, designed to assess safety and allergenicity in 243 healthy volunteers. The company anticipates submitting a Biological License Application (BLA) for marketing approval to the MFDS in the second half of 2025, pending trial outcomes. This milestone is a step toward advancing the HLB3-002 development program for subcutaneous delivery, potentially offering a more patient-friendly alternative to intravenous administration.

Analysis

Huonslab, a subsidiary of Huons Global (KOSDAQ:084110), has reported the successful completion of patient enrollment in its pivotal Phase 1 clinical trial (NCT06713317) for HLB3-002 (Hydizyme™), a recombinant human natural hyaluronidase PH20. This study, involving 243 healthy volunteers in South Korea, is designed to evaluate the safety and allergenicity of HLB3-002 through both intradermal and subcutaneous administrations. This milestone is a crucial step in the HLB3-002 development program, with Huonslab anticipating the submission of a Biological License Application (BLA) to South Korea's Ministry of Food and Drug Safety (MFDS) by the second half of 2025, contingent on positive trial results. HLB3-002, developed via Huonslab's proprietary HyDIFFUZE™ platform, aims to enhance subcutaneous drug delivery, positioning it as a potentially more patient-friendly and economical alternative to traditional intravenous methods, a concept that received attention at the AACR 2025 meeting. The overall sentiment surrounding this announcement is moderately positive (0.6 general score, 0.7 for ticker 084110), reflecting optimism about the progression of this asset within Huons Global's biologics R&D pipeline, though the market impact score of 0.35 suggests a measured immediate market reaction.

Key Decisions for Investors

• Investors should view the completion of Phase 1 enrollment for HLB3-002 as a positive, yet early-stage, de-risking event for Huons Global (084110), with critical trial data and the ambitious BLA submission timeline of 2H 2025 being key upcoming catalysts to monitor.
• The potential of the HyDIFFUZE™ platform and HLB3-002 to improve subcutaneous drug delivery could offer significant long-term value; however, this must be weighed against the inherent risks and timelines associated with pharmaceutical development and regulatory approvals.
• Closely track the forthcoming safety and allergenicity results from this pivotal Phase 1 study, as these outcomes will be fundamental to HLB3-002's progression and its potential contribution to Huons Global's portfolio.